Long-term results of combined preradiation chemotherapy and age-tailored radiotherapy doses for childhood medulloblastoma.

To reduce the sequelae of craniospinal irradiation (CSI) in children under 10 (≥3) years old and to improve the prognosis for high-risk medulloblastoma in adolescents, we adjusted postoperative chemotherapy and CSI doses to patients' stage and age. From 1986 to 1995, 73 patients entered the study. Children under 10 and adolescents with metastases, residual disease (RD) or stage >T3 received postoperative IV vincristine and high-dose (HD) ± intrathecal (IT) methotrexate, while standard-risk adolescents were given IV vincristine and IT methotrexate. Chemotherapy was followed by CSI (19.8 Gy for children <10; 36 Gy for adolescents), with a 54-Gy posterior fossa boost. Maintenance chemotherapy with lomustine and vincristine was administered for a year afterwards. A total of 39 children were under 10 of whom 20 had metastases. Response to chemotherapy was recorded in 70%, but 5-year EFS and OS were only 48 and 56%, respectively. Results were significantly worse for metastatic cases, patients under 10, those with RD, and those staged without MRI (unavailable early in the study). Efforts to preserve survivors' quality of life did not pay off, and most patients over 30 still depended on their parents' income and had severe cognitive/endocrine disabilities. In conclusion, despite a very high response rate with this preradiation HD methotrexate schedule, the outcome for high-risk medulloblastoma patients did not improve (especially when lower CSI doses were used) and patients still developed severe morbidities.
AuthorsMaura Massimino, Graziella Cefalo, Daria Riva, Veronica Biassoni, Filippo Spreafico, Emilia Pecori, Geraldina Poggi, Paola Collini, Bianca Pollo, Laura Valentini, Paolo Potepan, Ettore Seregni, Michela Casanova, Andrea Ferrari, Roberto Luksch, Daniela Polastri, Monica Terenziani, Federica Pallotti, Carlo Alfredo Clerici, Elisabetta Schiavello, Fabio Simonetti, Cristina Meazza, Serena Catania, Marta Podda, Lorenza Gandola
JournalJournal of neuro-oncology (J Neurooncol) Vol. 108 Issue 1 Pg. 163-71 (May 2012) ISSN: 1573-7373 [Electronic] United States
PMID22350379 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Vincristine
  • Methotrexate
  • Adolescent
  • Age Factors
  • Antineoplastic Agents (therapeutic use)
  • Cerebellar Neoplasms (drug therapy, radiotherapy)
  • Child
  • Child, Preschool
  • Cognition Disorders (diagnosis, etiology)
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Longitudinal Studies
  • Magnetic Resonance Imaging
  • Maintenance Chemotherapy (methods)
  • Male
  • Medulloblastoma (drug therapy, radiotherapy)
  • Methotrexate (therapeutic use)
  • Myelography
  • Nervous System Diseases (diagnosis, etiology)
  • Neuropsychological Tests
  • Radiotherapy Dosage
  • Retrospective Studies
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Vincristine (therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: